Cyclerion Therapeutics(CYCN.US)

Last Updated 19:00:00 ET
longbridge loading
Company Encyclopedia
View More
name
Cyclerion Therapeutics
CYCN.US
Cyclerion Therapeutics, Inc., a biopharmaceutical company, develops treatments for serious diseases serious diseases with novel sGC stimulators in both the central nervous system (CNS) and the periphery. It is developing Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator, which is in Phase 2 clinical trial to treat cardiovascular diseases; and Praliciguat, a systemic sGC stimulator for the treatment of rare kidney disease. It has a license agreement with Akebia to develop, manufacture, medical affair, and commercializes Praliciguat and other related products. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
1.949 T
CYCN.USMarket value -Rank by Market Cap -/-

Financial Score

13/02/2026 Update
B
BiotechnologyIndustry
Industry Ranking48/402
Industry medianC
Industry averageD
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreD
    • ROE-24.80%E
    • Profit Margin-77.02%E
    • Gross Margin60.23%A
  • Growth ScoreA
    • Revenue YoY1371.65%A
    • Net Profit YoY58.36%B
    • Total Assets YoY17.05%A
    • Net Assets YoY16.35%A
  • Cash ScoreB
    • Cash Flow Margin-129.83%D
    • OCF YoY1371.65%A
  • Operating ScoreD
    • Turnover0.3D
  • Debt ScoreA
    • Gearing Ratio8.42%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Cybin GAAP EPS of -$1.00 misses by $0.41

    businessinsider·
    US
    BBH
    +2.23%
    US
    HELP
    +3.33%
    US
    CYBN
    0.00%
    businessinsider·
    US
    BBH
    +2.23%
    US
    HELP
    +3.33%
    US
    CYBN
    0.00%

    Crystalys Therapeutics appoints Justin Thacker as CFO to aid Phase 3 trials of Dotinurad in gout treatment.

    Unusual Whales·
    US
    IBB
    +2.22%
    US
    SBIO
    +1.51%
    US
    BIB
    +4.80%
    Unusual Whales·
    US
    IBB
    +2.22%
    US
    SBIO
    +1.51%
    US
    BIB
    +4.80%

    Cytophage Technologies Appoints James Kinley as Chief Financial Officer

    Reuters·
    US
    IBB
    +2.22%
    US
    XBI
    +1.93%
    US
    FBT
    +2.40%
    Reuters·
    US
    IBB
    +2.22%
    US
    XBI
    +1.93%
    US
    FBT
    +2.40%

    Pre-market hot trades in US stocks: Cyclerion Therapeutics pre-market down 8.33%; Lockheed Martin pre-market up 7.47%

    Tracking Unusual Activity·
    US
    CYCN
    +0.41%
    US
    LMT
    +2.75%
    Tracking Unusual Activity·
    US
    CYCN
    +0.41%
    US
    LMT
    +2.75%

    Cyclerion Therapeutics Signs Collaboration and Option Agreement With Medsteer

    TradingView·
    US
    CYCN
    +0.41%
    TradingView·
    US
    CYCN
    +0.41%
    © 2026 Longbridge｜Disclaimer